Literature DB >> 17179461

Evaluation and management of patients after implantable cardioverter-defibrillator shock.

Anil K Gehi1, Davendra Mehta, J Anthony Gomes.   

Abstract

CONTEXT: There has been a tremendous increase in the use of implantable cardioverter-defibrillators (ICDs) after several large clinical trials demonstrated their ability to effectively reduce mortality in selected populations of patients with cardiac disease. Thus, the nonelectrophysiologist will often encounter patients who have received an ICD shock.
OBJECTIVE: To assess options for the evaluation and management of patients who have received an ICD shock. EVIDENCE ACQUISITION: Literature search using the PubMed and MEDLINE databases to identify articles published from January 1990 to September 2006, using the Medical Subject Headings defibrillators, implantable; defibrillators, implantable/adverse effects; anti-arrhythmic agents; electric countershock; quality of life; tachycardia therapy; algorithm; ventricular tachycardia/diagnosis; and supraventricular tachycardia/diagnosis. Case reports were excluded and articles were limited to those published in English. Scientific statements and guidelines from the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society were also reviewed, as were the reference lists of retrieved articles, to identify any additional articles for inclusion. EVIDENCE SYNTHESIS: There are multiple causes of both appropriate and inappropriate ICD shocks. Irrespective of appropriateness, receiving ICD shocks substantially impairs a patient's quality of life. A variety of techniques are available using ICD programming to reliably limit the occurrence of appropriate or inappropriate ICD shocks. Antiarrhythmic medications can also effectively reduce the occurrence of shocks.
CONCLUSIONS: Through the use of effective ICD programming and antiarrhythmic medications, the occurrence of ICD shocks can be reduced while maintaining the lifesaving ability of the ICD. A basic understanding of the range of available options is fundamental for evaluation and management of the patient who has received an ICD shock.

Entities:  

Mesh:

Year:  2006        PMID: 17179461     DOI: 10.1001/jama.296.23.2839

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  Factors associated with medication adherence among heart failure patients and their caregivers.

Authors:  Brooke Aggarwal; Ashley Pender; Lori Mosca; Heidi Mochari-Greenberger
Journal:  J Nurs Educ Pract       Date:  2015

2.  Performance of an ICD algorithm to detect lead noise and reduce inappropriate shocks.

Authors:  Scott Beau; Stephen Greer; Christopher R Ellis; Jeffrey Keeney; Shubha Asopa; Edith Arnold; Avi Fischer
Journal:  J Interv Card Electrophysiol       Date:  2016-01-06       Impact factor: 1.900

3.  Implantable cardioverter defibrillator therapy: a single center experience in saudi arabia.

Authors:  Ahmad S Hersi
Journal:  Open Cardiovasc Med J       Date:  2010-09-28

4.  Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia.

Authors:  Christian Eickholt; Marcus Siekiera; Kiriakos Kirmanoglou; Astrid Rodenbeck; Nicole Heussen; Patrick Schauerte; Artur Lichtenberg; Jan Balzer; Tienush Rassaf; Stefan Perings; Malte Kelm; Dong-In Shin; Christian Meyer
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

Review 5.  Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.

Authors:  Juan Carlos Claro; Roberto Candia; Gabriel Rada; Fernando Baraona; Francisco Larrondo; Luz M Letelier
Journal:  Cochrane Database Syst Rev       Date:  2015-12-08

6.  Programmed inappropriate ICD ventricular defibrillation for cardioversion of persistent atrial fibrillation.

Authors:  Panagiotis Korantzopoulos; George Grekas; Thomas Pappas; John A Goudevenos
Journal:  Cases J       Date:  2008-09-12

7.  Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial.

Authors:  William L Baker; Jeffrey Kluger; Craig I Coleman; C Michael White
Journal:  Open Cardiovasc Med J       Date:  2015-10-30

8.  Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Daniel P Morin; Carme Perez-Quilis; Jari A Laukkanen; Marco V Perez
Journal:  Am J Cardiovasc Drugs       Date:  2020-10       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.